Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/9/2008

Keryx to Host Investor Conference Call on Monday, May 12, 2008 at 8:30am

EDT

NEW YORK, May 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the first quarter ended March 31, 2008.

At March 31, 2008, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $47.6 million, as compared to $64.7 million at December 31, 2007. In April 2008, we received a payment of $8.0 million that was classified as a license receivable at March 31, 2008. The payment was made pursuant to the September 2007 licensing agreement among Keryx, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

The net loss for the first quarter ended March 31, 2008 was $34,536,000, or $0.79 per share, compared to a net loss of $21,813,000, or $0.50 per share, for the first quarter in 2007, representing an increase in net loss of $12,723,000. The increase in net loss was primarily attributable to costs associated with the cessation of our development of Sulonex. Such costs included an $11,037,000 non-cash impairment charge related to the write-down of the assets of the Sulonex manufacturing suite to their estimated fair value, and a $2,063,000 provision for estimated costs relating to the required restoration of the manufacturing facility to its original condition, partially offset by a decrease of $2,264,000 in non-cash compensation expense, primarily related to stock options and restricted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... September 30, 2014 Shimadzu Scientific ... an easy-to-use and highly precise tool for measuring ... considerable elongation. With 1000-mm maximum movement distance, the ... for a gauge length of 10 mm. In ... accuracy above 50-mm stroke and within +/- 100 ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market is ... increased acceptance of new filtration technologies in end users ... also catalyzing the growth of laboratory filtration market. , ... at a strong CAGR during the forecast period of ... by 2019. The market is mainly driven by the ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... increased 14% over third quarter 2007 to $201 million, ... AMLN ) today reported financial results for the ... of $218.4 million,for the third quarter, including net product ... period in 2007. Net loss for the quarter ended,September ...
... Foundation, a,nonprofit organization that funds research in early cancer ... Gambhir, has,been elected as a new member of the ... of the highest honors in the fields of health,and ... Academy of,Sciences, serves as adviser to the nation to ...
... is effective when ... applications and vaccines, ANN ARBOR, Mich., Oct. 21 ... new data in nine presentations that,detail key milestones in ... cystic fibrosis and an intra-nasal,influenza vaccine during the joint ...
Cached Biology Technology:Amylin Pharmaceuticals Reports Third Quarter Financial Results 2Amylin Pharmaceuticals Reports Third Quarter Financial Results 3Amylin Pharmaceuticals Reports Third Quarter Financial Results 4Amylin Pharmaceuticals Reports Third Quarter Financial Results 5Amylin Pharmaceuticals Reports Third Quarter Financial Results 6Amylin Pharmaceuticals Reports Third Quarter Financial Results 7Amylin Pharmaceuticals Reports Third Quarter Financial Results 8Canary Foundation's Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine 2NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
(Date:9/29/2014)... 29: Between 1970 and 2010 populations of mammals, ... dropped 52 percent, says the 2014 Living Planet ... This biodiversity loss occurs disproportionately in low-income countriesand ... countries. , In addition to the precipitous decline ... other warning signs about the overall health of ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2
... The American Society for Neural Therapy and Repair (ASNTR), holding ... Clearwater Beach, Florida, has awarded The 2009 Bernard Sanberg Memorial ... Executive Vice President for Health Services and Executive Dean of ... is named for Bernard Sanberg, father of Dr. Paul Sanberg, ...
... Scientists funded by the National Institutes of Health have ... causes disabling daytime sleepiness, sleep attacks, irresistible bouts of ... sleep at night. The gene has a known role ... in which the immune system turns against the body,s ...
... to offer new treatment options following surgery for patients ... the first European Multidisciplinary Conference in Thoracic Oncology (EMCTO) ... is the key strategy for longer and better survival ... the second Medical Oncology Department at Hygeia Hospital in ...
Cached Biology News:Georgetown University's Howard J. Federoff, M.D., Ph.D. receives Bernard Sanberg Memorial Award 2Genetic study confirms the immune system's role in narcolepsy 2Genetic study confirms the immune system's role in narcolepsy 3Personalized treatment for early lung cancer 2
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
Biology Products: